Why Crocs (CROX) stock jumped nearly 20% after earnings — and what to watch Friday

Why Crocs (CROX) stock jumped nearly 20% after earnings — and what to watch Friday

February 13, 2026

New York, Feb 12, 2026, 19:26 ET — Trading after the bell

Shares of Crocs, Inc. surged roughly 19% in after-hours action on Thursday, changing hands most recently at $98.46. The casual-footwear company posted its quarterly numbers and shared its outlook heading into 2026.

This time, CROX is back in the spotlight—shares tend to swing hard after earnings, and the debate isn’t settled. Investors can’t agree: Is demand for Crocs just cooling off, or is something worse coming? Heydude, which is still the unpredictable part of the story, hasn’t cleared things up.

Crocs is pushing more product through its own websites and shops, dialing back reliance on wholesale, where demand has lagged. The main question on traders’ minds: does this channel shift actually shield margins, or is it just a temporary cover for weaker momentum?

Crocs reported a 3.2% drop in fourth-quarter revenue, bringing in $958 million, with adjusted (non-GAAP) diluted EPS at $2.29. Direct-to-consumer sales climbed 4.7%, but wholesale tumbled 14.5%. The Crocs brand managed a 0.8% uptick to $768 million; Heydude, on the other hand, slumped 16.9% to $189 million.

That topped the IBES numbers, where analysts had been looking for $1.90 per share on $922.3 million in revenue.

Chief Executive Andrew Rees said results for the holiday quarter topped expectations, adding that Crocs has mapped out roughly $100 million in cost cuts for 2026, even as it plans to keep putting money into both brands. The company disclosed it bought back around 6.5 million shares for $577 million in 2025 and reduced debt by $128 million.

Crocs is guiding for a first-quarter revenue drop of 3.5% to 5.5% from a year ago, with adjusted EPS pegged between $2.67 and $2.77. Looking further out, the company sees 2026 revenue anywhere from a 1% dip to a modest uptick, and expects adjusted EPS to land between $12.88 and $13.35—both ahead of Visible Alpha estimates, according to Investopedia.

The early read on 2026 isn’t inspiring—Heydude is set to decline once more, and North American demand looks shaky. Rees told analysts on the call that “no significant price changes” are baked in for North America. Executives also highlighted tariff pressures they’re working to counter by tweaking the supply chain. The Motley Fool

Crocs submitted its 8-K on Thursday, the document signed by CFO Patraic Reagan and attaching the earnings release as an exhibit, according to the filing.

Needham bumped its price target on Crocs up to $118 from $100, sticking with its buy call after earnings. The firm pointed to the solid results and what it described as upbeat guidance.

The real test comes next: Will Thursday’s post-earnings pop stick around when Friday’s regular session hits, Feb. 13? More broker notes will drop, traders will move past the headlines, and attention will shift to what’s actually happening with Crocs, Heydude, and wholesale trends.

Marcin Frąckiewicz

Marcin Frąckiewicz is the CEO of TS2 Space and a longtime technology entrepreneur focused on telecommunications, satellite communications and digital innovation. A graduate of the Warsaw School of Economics (SGH), he writes about space technology, artificial intelligence and publicly traded technology companies. His analysis covers major market trends, emerging technologies and the businesses shaping the future of the global economy.

Stock Market Today

  • ASX Growth Stocks With High Insider Stakes Draw Focus
    July 12, 2026, 1:01 AM EDT. Some fast growing ASX stocks with high insider ownership are catching attention as markets react to inflation and rate moves. Predictive Discovery (ASX:PDI), with a market cap of A$3.45 billion, is building a gold hub in West Africa based on a 9.5 million ounce resource, even as it remains loss-making. Telix Pharmaceuticals (ASX:TLX), worth A$5.52 billion, sells radiopharmaceuticals for cancer and reports revenue from precision medicine, with more treatments in its pipeline. Both names bring growth exposure where management has skin in the game, something investors watch for when insiders and holders are aligned. But funding, regulation, and emerging market risk remain.